RNA carries instructions copied from DNA, but those instructions do not automatically determine how a cell functions. Messenger RNA must be stabilized, transported and translated at the right time and in the right amount. m6A modification acts as part of this regulatory system. Specialized proteins known as “writers” add the methyl group to RNA, “erasers” remove it, and “readers” recognize the mark and determine what happens to the modified molecule. This dynamic network is particularly important in the developing brain, where neural stem cells must produce different types of neurons and glial cells in precise sequences.

During brain development, balanced m6A activity helps control whether neural stem cells continue dividing, remain in an undifferentiated state or mature into specialized cells. It also influences the formation of neuronal connections, the production of myelin and the activity of immune cells in the nervous system. These processes depend on carefully timed changes in gene expression. If RNA molecules are stabilized for too long, destroyed too quickly or translated inefficiently, the consequences can include abnormal neural development, impaired communication between neurons and reduced resilience to later damage.

The review describes evidence that disrupted m6A regulation is associated with several neurological disorders, including Alzheimer’s disease, Parkinson’s disease and epilepsy. In these conditions, abnormal RNA methylation may affect pathways involved in neuronal survival, synaptic plasticity, inflammation, oxidative stress and the accumulation of misfolded proteins. In Alzheimer’s disease, for example, altered m6A signaling has been linked to mechanisms associated with memory impairment and pathological protein deposition. In Parkinson’s disease, the same regulatory system may influence the vulnerability of dopamine-producing neurons and the inflammatory responses that contribute to their loss.

The connection between m6A and environmental toxicants is especially significant because the chemicals discussed in the review act through different biological pathways. Manganese exposure can interfere with mitochondrial function and neuronal signaling, while arsenite can trigger oxidative stress and damage proteins involved in cellular defense. Aluminum has been investigated for its potential effects on inflammation and protein homeostasis, and cobalt can alter cellular responses to oxygen availability and metabolic stress. The anesthetic sevoflurane, meanwhile, has been studied for possible effects on developing brains, particularly in relation to inflammation, neuronal survival and cognitive function. The review brings these apparently different hazards together through their potential impact on RNA regulation.

Toxicants may disturb the m6A system by changing the activity or abundance of methylation “writers,” demethylation “erasers” or RNA-binding “readers.” They may also alter the cellular environment in which these proteins operate. Oxidative stress, disrupted energy production, abnormal immune signaling and changes in cellular metabolism can all influence RNA modification. Because m6A controls many RNA molecules at once, even a modest disturbance could affect multiple biological systems, including synaptic function, neurodevelopment, inflammatory signaling and the brain’s ability to repair itself.

This mechanism may also help explain why the timing of exposure matters. A toxicant encountered during early development could interfere with neural stem-cell decisions or the establishment of neural circuits, potentially producing effects that become visible only later in life. Exposure in adulthood may instead accelerate inflammation, impair neuronal maintenance or reduce the brain’s ability to respond to injury. The review emphasizes that m6A is not simply a marker of damage; it may be part of the process through which environmental stress is translated into long-term changes in nervous-system function.

The findings point toward possible therapeutic strategies, although they remain at an early stage. Drugs designed to adjust the activity of m6A writers or erasers could, in principle, restore healthier patterns of RNA regulation. Modifying reader proteins might alter the fate of specific RNA molecules without changing the entire methylation system. Another approach involves exosomes, naturally occurring membrane-bound particles that transport RNA and proteins between cells. Because some exosomes can cross the blood-brain barrier, researchers are investigating whether they could deliver protective molecules or RNA-based therapies to vulnerable regions of the central nervous system.

The authors caution that the relationship between m6A, toxicant exposure and neurological disease is complex. The effects of RNA methylation can vary according to cell type, developmental stage, exposure level and the specific RNA molecules involved. A change that protects one population of cells could be harmful in another, and results observed in experimental models may not directly predict human outcomes. More research is needed to identify reliable biomarkers of toxicant-related RNA disruption, determine whether m6A changes are a cause or consequence of disease, and establish treatments that can act on the pathway safely.

By connecting environmental toxicology with epitranscriptomics—the study of chemical changes that regulate RNA—the review offers a broader framework for understanding how external exposures can influence brain health. m6A may ultimately become useful both as an indicator of neurological stress and as a target for intervention. For now, the emerging evidence suggests that the consequences of toxicant exposure are written not only in damaged cells or altered DNA, but also in the constantly changing chemical instructions carried by RNA.

Subject of Research: The role of N6-methyladenosine (m6A) RNA modification in neural development and toxicant-related neurodegeneration.

Article Title: Interaction between N6-methyladenosine (m6A) modification and toxicant-related neurodegeneration: From neural development to pathophysiology

Web References: https://doi.org/10.1016/j.gendis.2025.101984

References: Zhou She, Peng Huang, Senlin Luo, Lu Zhang, Hong Peng, Yufen Tang, Yuqiong Chen, Jinwen Luo, Wangxin Duan, Lingjuan Liu, Liqun Liu, “Interaction between N6-methyladenosine (m6A) modification and toxicant-related neurodegeneration: From neural development to pathophysiology,” Genes & Diseases, Volume 13, Issue 5, 2026, Article 101984.

Image Credits: Genes & Diseases

Keywords: m6A RNA methylation, epitranscriptomics, RNA modification, brain development, neural stem cells, neurodegeneration, environmental toxicants, manganese, arsenite, aluminum, cobalt, sevoflurane, Alzheimer’s disease, Parkinson’s disease, epilepsy, exosomes, blood-brain barrier.

RNA-binding proteins (RBPs) are integral players in the post-transcriptional regulation of gene expression, influencing RNA processing, stability, localization, and translation. CMSS1, a ribosomal small subunit homolog, has recently attracted interest due to its aberrant expression in various cancers, yet its specific role in NSCLC has been largely enigmatic until now. The current study employed comprehensive bioinformatics analyses, coupled with experimental validation, to elucidate the functional and clinical relevance of CMSS1 in NSCLC.

Researchers utilized The Cancer Genome Atlas (TCGA) database to identify differentially expressed RBPs in NSCLC tissue compared to normal lung tissue. Among these, CMSS1 emerged as a significantly upregulated gene. This elevated expression pattern prompted further investigation into whether CMSS1 could serve as a prognostic biomarker. Using univariate Cox regression and Kaplan-Meier survival analyses, high CMSS1 RNA levels were conclusively associated with poorer overall survival in patients, suggesting its potential as a predictive indicator of disease outcome.

To uncover prognostic robustness, time-dependent receiver operating characteristic (ROC) curves and multivariate Cox regression models were applied, confirming CMSS1’s independent prognostic value beyond traditional clinical parameters. The ability to stratify patients based on CMSS1 expression levels could revolutionize NSCLC prognosis by enabling more precise risk assessments and individualized treatment planning.

Beyond its prognostic significance, the study delved into the immunological landscape surrounding CMSS1 expression. Utilizing the ImmuCellAI algorithm, which predicts immune cell infiltration from transcriptomic data, researchers discovered a complex relationship between CMSS1 levels and immune subsets within the NSCLC tumor microenvironment. Notably, CMSS1 expression was negatively correlated with CD4+ T cell infiltration, key players in orchestrating anti-tumor immunity, whereas a positive correlation was observed with immunosuppressive populations such as regulatory T cells (Tregs) and macrophages.

This immunomodulatory association hints at CMSS1’s potential role in fostering an immunosuppressive milieu that could facilitate tumor immune evasion and progression. Such findings underscore the importance of integrating molecular and immunological data to fully comprehend tumor biology and identify combinatory therapeutic targets.

Validating bioinformatics insights, the researchers conducted experimental assays on NSCLC cell lines. Reverse transcription quantitative PCR (RT-qPCR) and western blot analyses corroborated the heightened RNA and protein expression of CMSS1 in cancerous versus normal lung cells. These molecular confirmations strengthen the reliability of database-driven discoveries and affirm CMSS1 as a bona fide player in NSCLC pathology.

To dissect CMSS1’s functional role, loss-of-function assays using gene silencing techniques were performed. The downregulation of CMSS1 dramatically impaired NSCLC cell viability, migration, and invasive capabilities in vitro, demonstrating its direct contribution to tumor aggressiveness. These cellular phenotypes align with the clinical data, reinforcing the protein’s oncogenic attributes.

From a mechanistic perspective, while the study primarily focused on CMSS1’s prognostic and immunological correlations, its designation as a ribosomal small subunit homolog positions it as a modulator of translational control. Aberrant regulation of ribosomal RBPs frequently impacts protein synthesis profiles that favor malignant phenotypes, implicating CMSS1 as a critical node in tumor-promoting gene expression networks.

The implications of targeting CMSS1 therapeutically are profound. Given its tumor-specific overexpression and influence on immune infiltration and tumor cell behavior, CMSS1 presents itself as a dual-faceted candidate for intervention. Inhibiting CMSS1 could suppress tumor growth while potentially reshaping the tumor immune contexture towards enhanced anti-tumor immunity.

This study also provides a platform for future research to explore CMSS1’s interactions with other oncogenic pathways and immune checkpoints, possibly unveiling synergistic combinations with existing immunotherapies. As NSCLC treatment paradigms increasingly embrace precision medicine, integrating CMSS1 expression profiling could guide therapeutic decisions and optimize patient outcomes more effectively.

Moreover, the research community is encouraged to investigate the upstream regulatory mechanisms governing CMSS1 expression in NSCLC, which may reveal additional targets for intervention or biomarkers for early detection. Such efforts could culminate in a comprehensive molecular framework defining NSCLC progression.

The value of this research extends beyond NSCLC, as aberrant RBP function is a hallmark of multiple cancers. Deciphering CMSS1’s role may inspire analogous studies in different tumor types, broadening our understanding of RNA-binding proteins in oncology.

In conclusion, the elucidation of CMSS1’s involvement in NSCLC progression, immune modulation, and patient prognosis marks a significant advancement in lung cancer research. This work not only identifies CMSS1 as an emergent biomarker but also as a promising therapeutic target, offering hope for improved clinical management of a notoriously lethal disease.

As the fight against NSCLC intensifies, findings such as these illuminate the intricate molecular interplay that underlies cancer’s resilience, serving as a beacon for innovative treatments that leverage the nuanced regulation of RNA-binding proteins. The translation of these insights into clinical practice could ultimately elevate the standard of care and survival rates for patients grappling with NSCLC.

Subject of Research: Roles of the RNA-binding protein CMSS1 in non-small cell lung cancer progression and prognosis.

Article Title: CMSS1: A RNA binding protein with pivotal roles in non-small cell lung cancer progression and prognosis.

Article References:
Fan, Z., Liu, W., Gao, Z. et al. CMSS1: A RNA binding protein with pivotal roles in non-small cell lung cancer progression and prognosis. BMC Cancer 25, 688 (2025). https://doi.org/10.1186/s12885-025-14044-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14044-9